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Conclusion: Ivabradine or atenolol can be used for heart rate
control in moderate MS patients in sinus rhythm. Ivabradine is
not superior to atenolol for controlling heart rate or exercise ca-
pacity. Left ventricular MPI was unaffected byeither of the drugs.
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Background: Percutaneous balloon mitral valvotomy (PBMV) is
well established as a safe and effective alternative to mitral ste-
nosis surgery, but only a few small studies have been reported on
the procedure. The aim of this study is to assess the safety, effi-
cacy and outcome of PBMV in Shahid Gangalal National Heart
Centre, Kathmandu, Nepal.
Methods: 262 consecutive patients who underwent balloon val-
votomy for moderate to severe mitral stenosis between July 1st
2013 to June 31st 2014 in our centre were analyzed.
Results: Among 262 patients, 74% percent of the patients were
females. Their age range was from 10years to 76years and mean
age was 33.2years. 70 (26.7%) patients were in atrial fibrillation; 6
(2%) patients were pregnant; 3 (1%) patients had Cerebrovascular
Accident; 12 (4.6%) patients underwent previous surgical or
balloon commissurotomy. The procedural success was achieved
in 84% patients. The mean left atrial pressure was reduced from
26.8 ± 8.9 mmHg to 15.6 ± 7.2 mmHg (p < 0.05).The mean mitral
valve area assessed by 2-D echocardiography increased from 0.9 ±
0.17 cm2 to 1.6 ± 0.28 cm2 (p < 0.05). 49 patients (18.7%) developed
moderate to severe mitral regurgitation. There was no mortality
related to the procedure.
Conclusion: The results of this study show that PBMV is a safe
procedure with good success rate for symptomatic mitral stenosis
with low complication rates and good clinical improvement.
Study of effectiveness and safety of percutaneous
mitral valvuloplasty for the treatment of pregnant
patients with mitral stenosis
Pooja Vyas, Jagjeet, Naveen Sharma, Sibasish Sahoo,
Anand Shukla, Jayesh Prajapati
U N Mehta Institute of Cardiology, Ahmedabad, India
Background: Mitral stenosis is one of the most frequently
encountered cardiac abnormalities in women of child- bearing
age, accounting for nearly 90% of the cases of rheumatic heart
disease associated with pregnancy. This study was done to eval-
uate the safety and effectiveness of percutaneous balloon mitral
valvuloplasty (BMV) with severemitral stenosis during pregnancy.
Methods: A total of 30 pregnant patients were included in the study
after detailed echocardiographic evaluation. Clinical and echocar-
diographic follow-up were done by hospital visits every 3 months
after the procedure until delivery and at 6 months follow up.
Results: 14 (46.67%) patients underwent BMV during the third
trimester of pregnancy, whereas 16 (53.3%) had the procedure
performed in the second trimester. Mean gestational Age at the
time of procedure was 25.3 ± 3.93 weeks. 2 (6.6%) were in NYHA
class IV, 14 (46.7%) were in III and the remaining 14 (46.7%) of
patients were in NYHA class II.19 (63.33%) patients had a Wilkin’s
score of <8, and 11 (36.67%) had a score of >8. 29(96.3%) patients
had moderate or severe pulmonary artery hypertension, with
mean Pulmonary artery systolic pressure 68.23±23.28
mmHg.There was no maternal mortality. One patient developed
severe mitral regurgitation which underwent successful emer-
gency surgical mitral valve replacement. No patient had cere-
brovascular stroke/TIA or any vascular complications. The mean
mitral valve area was 0.85+0.16 cm2 before BMV and increased to
1.60+0.27 cm2 (p<0.0001) immediately after BMV. Peak and mean
diastolic gradients had decreased significantly 48 hours after the
procedure (p<0.001) but remained very much unchanged at 6.72
month follow-up compared with post procedure values .Two pa-
tients had an increase in mitral regurgitation by 2 grades. The
mean follow up duration was 6.72±0.56 months. 3 (11.11 %)
delivered before term.7 (25.91%) babies were having birth weight
less than 2.5 kg.
Conclusion: This study further supported the impression that
BMV was the procedure of choice to treat pregnant women with
rheumatic mitral stenosis in NYHA class II to IV. In this popula-
tion, BMV was a safe and effective procedure that resulted in
excellent immediate and intermediate-term outcomes for
mothers and their offspring.
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Background: Prosthetic heart valve thrombosis (PHVT) occurs
frequently in developing countries and causes major morbidity
andmortality. The study was done to evaluate clinical, laboratory,
and diagnostic profile of patients admitted in emergency room
with obstructive PHVT and to study efficacy, outcomes and com-
plications of thrombolytic therapy and surgical therapy for
obstructive PHVT.
Methods: A total of 82 patients with PHVT in form of acute or sub-
acute dyspnoea (<1 month) or embolic phenomena were enrolled
and confirmed with either transthoracic or trans oesophageal
echo and cine fluoroscopy and were followed up for 2 years.
Results: 29.27% patients were adequately anticoagulated on
admission while 70.73% patients were not. 97.6% cases involved
mitral while 2.4% cases involved aortic prosthesis. 94% cases had
normal left ventricular function on admission, and 91% cases had
moderate to severe pulmonary artery hypertension. Treatment
option was chosen on basis of clinical characteristics, thrombus
load, affordability, patient’s and surgeon’s preference. 67 (81.7%)
patients were treated with thrombolysis by streptokinase (88%) or
urokinase (12%), and 12(14.6%) patients undergone surgery,
3(3.6%) patients undergone surgery after failed thrombolysis. In
thrombolysis group, complete success rate was 67.16%, mortality
rate was 14.92 %, recurrence rate at 2-yr follow up was 11.94%,
while in surgery group complete success rate was 92.3%,mortality
rate was 7.7%, recurrence rate at 2-yr follow up was 23.07%.
Conclusion: Compared to surgical therapy, thrombolysis in pa-
tients with PHVT was found to have higher mortality and
complication rates but with lower recurrence rates of valve
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thrombosis.NYHA functional class, LV function, site of valve, and
recurrent episodes were major determinants of successful
thrombolysis.
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Background: Presence of clinically significant coronary artery
disease (CAD) in patients undergoing valvular surgery is common
cause of post-operative complication and poor outcome.The cur-
rent study was designed to study overall prevalence of CAD andits
risk factors in patients affected by rheumatic heart disease (RHD).
Methods: A total of 757 consecutive rheumatic heart disease pa-
tients planned for valvular surgery who had undergone routine
coronary angiography in our Institute were examined. Presence of
clinically significant CAD was considered if one or more arteries
showed  50% stenosis in angiographic profile. Patients were
randomly divided into two groups e Group A (RHD with CAD) and
Group B (RHD without CAD), and were screened for the presence
of various coronary artery disease risk factors.
Results: The overall prevalence of CAD in the patients undergoing
valvularsurgery was 9.11%. The incidence of CAD in patients with
mitral, aortic and double valve replacement were 24.13%, 10.81%
and 6.15% respectively. The presence of smoking habit (33.3% vs.
20.9%) (p¼0.02), diabetes (24.6% vs. 3.1%) (p<0.0001), hypertension
(21.7% vs. 6.8%) (p<0.0001) and family history of CAD (17.4% vs.
8.3%) (p<0.02) was significantly higher in group A as compared to
group B. In Group A, single vessel disease, double vessel disease
and triple vessel diseasewere seen in 55.1%, 29% and 15.9 % cases
respectively.In RHD patients, the most commonly involved vessel
was LAD (left anterior descending artery) (63.7% overall and 30.4%
alone) followed by LCX (left circumflex artery) (59.04%) and RCA
(right coronary artery) (34.7%).
Conclusion: Prevalence of CAD in patients with RHD in Gujarat,
India waslower than that in western countries and was seenmore
frequently in patients with mitral valve disease. Single vessel
involvement, mostly LAD was more common among these pa-
tients. CAD in RHD patients was associated with the presence of
multiple identifiable coronary risk factors.
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Background: Thrombosis is a serious and life threatening
complication following cardiac valve replacement and is a com-
mon cause of referral to the higher centre for intervention.
Although surgery has been described as the traditional choice of
therapy for the PVT all over the world, thrombolytic therapy is a
promising alternative to valve re-operation in PVT.
Methods: Twelve consecutive patients (6males, 6 females) (2 AVR,
9 MVR and 1 DVR) were included in the study from January 2013 to
January 2014. Mean age were 29±10 years. Diagnosis is confirmed
both by TTE and fluoroscopy. Mean gradient of patients with
mitral PVT were 24.4±4.86 and for aortic PVT was 43.3±13.1. All
patients were taking Acenocumarol derivatives. INR on presen-
tation was 1.79±0.34 and 2.53±1.31 for aortic and mitral PVT.
Thrombus burden was measured in all patients by TEE. Ten-
ecteplase is given at a dose of 0.5mg/ kg bolus in all the patients
with clinical and Echocardiographic examinations repeated at 6
and 24 hours after starting thrombolytic therapy. Doppler echo-
cardiography was the primary method to follow for response to
therapy.
Results: Thrombolytic therapy was successful in all the patients.
Mean gradient decrease to 10.3±3.4mmhg and 5.7±3.1 mmhg at 6
and 24 hours for mitral valve (p<0.001) and 8.2±4.6 mmhg and
5.8±2.5 mmhg for aortic valve (p¼<0.001). Leaflets movements
were complete in 7 and partial in 5 patients. Thrombus burden
significantly reduced in all the patients. Two patients had CVA
(infarct) and 1 had large sheath site hematoma. None of the pa-
tients expired. At 6 months follow up, Mean gradient were
8.3±2.8mmhg and 10.3±4.72mmhg for mitral and aortic valve. All
patients were asymptomatic with no complications on follow up.
Conclusion: Present study demonstrates that Tenectaplase is a
safe, feasibile and effective thrombolytic treatment for patients
with PVT and should be considered as first line therapy for pros-
thetic heart valve thrombosis.
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Background: Pure HR reduction with Ivabradine without unde-
sirable hemodynamic side effect associated with B-blockers may
be better for symptomatic improvement in mitral stenosis (MS)
patients with normal sinus rhythm (NSR).
Methods: 100 mitral stenosis patients with NSR were randomized
in a ratio of 1:1 to receive either Ivabradine (5mg-BD) or atenolol
(50mg-OD) for 12 weeks. Clinical assessment, TMT and echo-
Doppler evaluation was done to compare efficacy and side effect
of two drugs.
Results: Mean dose of Ivabradine and Atenolol was 6.05±1.25mg
and 60±26.7 mg respectively at 12 weeks. Results are shown in
table. Resting HR reduction was similar in both groups. On TMT
peak HR reduction, increase in Total exercise duration & Time of
Symptom onset showed similar improvement in both groups.
MDG& EDG reductionwas similar in both groups. Significant RVSP
reduction was seen in Ivabradine group but not in Atenolol group.
NYHA class showed similar improvement with both drugs. Total
13 drug side effects were noticed. 2 in Ivabradine and 11 in aten-
olol group. There was 1 case of bradycardia in each group, 10 pa-
tients complained of increased fatigability with Atenolol.1 patient
had visual symptoms with Ivabradine.
Conclusion: Ivabradine is a useful alternative to B-blockers
treatment in patients with symptomatic mitral stenosis, having
efficacy similar to B-blockers with lower side effects.
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